Mitsubishi UFJ Asset Management
APLS

Mitsubishi UFJ Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-97
Closed -$3.9K – 1661
2026
Q1 		$3.9K Hold
97
– – ﹤0.01% 1531
2025
Q4 		$2.51K Hold
97
– – ﹤0.01% 1581
2025
Q3 		$2.19K Hold
97
– – ﹤0.01% 1569
2025
Q2 		$1.68K Hold
97
– – ﹤0.01% 1594
2025
Q1 		$2.12K Hold
97
– – ﹤0.01% 1574
2024
Q4 		$3.25K Hold
97
– – ﹤0.01% 1530
2024
Q3 		$2.8K Hold
97
– – ﹤0.01% 1548
2024
Q2 		$3.72K Hold
97
– – ﹤0.01% 1464
2024
Q1 		$5.7K Hold
97
– – ﹤0.01% 1300
2023
Q4 		$5.82K Hold
97
– – ﹤0.01% 1267
2023
Q3 		$3.69K Buy
+97
New +$4.26K ﹤0.01% 1354

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mitsubishi UFJ Asset Management's APLS Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 97 shares — an estimated $3.9K sold.

Mitsubishi UFJ Asset Management first reported a position in APLS in Q3 2023 and held it in 11 quarters. The position peaked at $5.82K in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Mitsubishi UFJ Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 97 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.9K.
  • Mitsubishi UFJ Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Mitsubishi UFJ Asset Management's Apellis Pharmaceuticals position peaked at $5.82K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.